

Permission for non-commercial translation and distribution of ESMO Clinical Practice Guidelines

This Agreement is made on this day, **29 November 2013** between:

The **European Society for Medical Oncology (ESMO)**, a company registered in Switzerland, with its office at Via Luigi Taddei 4, 6962 Viganella-Lugano, Switzerland and represented by Mr. Keith McGregor, ESMO Senior Director for Business Development & Strategy.

and:

Association of medicinal oncologists of Republic of Srpska, Bosnia and Herzegovina (hereinafter referred to as Association of medicinal oncologists) an organization registered in the country of **Bosnia and Herzegovina** with its office at **Banja Luka** and represented by **Gordana Kecman Malčić**.

ESMO grants the **Association of medicinal oncologists** permission to translate, print and distribute the following ESMO Clinical Practice Guideline title in the **serbian** language for distribution only in the country of **Bosnia and Herzegovina** for a period of one year from the date of this agreement, which is non-exclusive.

1. Oesophageal Cancer: ESMO Clinical Practice Guidelines; Published in 2013 – Ann Oncol 2013; 24 (Suppl 6): vi51-vi56. Authors: M. Stahl, C. Mariette, K. Haustermans, A. Cervantes, D. Arnold
2. Gastric Cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines; Published in 2013 – Ann Oncol 2013; 24 (Suppl 6): vi57-vi63. Authors: T. Waddell, M. Verheij, W. Allum, D. Cunningham, A. Cervantes, D. Arnold
3. Early Colon Cancer: ESMO Clinical Practice Guidelines; Published in 2013 – Ann Oncol 2013; 24 (Suppl 6): vi64-vi72. Authors: R. Labianca, B. Nordlinger, G. D. Beretta, S. Mosconi, M. Mandalà, A. Cervantes, D. Arnold
4. Familial Risk-Colorectal Cancer: ESMO Clinical Practice Guidelines; Published in 2013 – Ann Oncol 2013; 24 (Suppl 6): vi73-vi80. Authors: J. Balmaña, F. Balaguer, A. Cervantes, D. Arnold
5. Rectal Cancer: ESMO Clinical Practice Guidelines; Published in 2013 – Ann Oncol 2013; 24 (Suppl 6): vi81-vi88. Authors: B. Glimelius, E. Tiret, A. Cervantes, D. Arnold
6. Pancreatic Adenocarcinoma: ESMO Clinical Practice Guidelines; Published in 2012 – Ann Oncol 2012; 23 (Suppl 7): vi33-vi40. Authors: T. Seufferlein, J.B. Bachet, E. Van Cutsem, P. Rougier
7. Hepatocellular Carcinoma: ESMO-ESDO Clinical Practice Guidelines; Published in 2012 – Ann Oncol 2012; 23 (Suppl 7): vi41-vi48. Authors: C. Verslype, O. Rosmorduc, P. Rougier
8. Biliary Cancer: ESMO Clinical Practice Guidelines; Published in 2011 – Ann Oncol 2011; 22 (Suppl 6): vi40-vi44. Authors: F. Eckel, T. Brunner, S. Jelic
9. Advanced Colorectal Cancer: ESMO Clinical Practice Guidelines; Published in 2010 – Ann Oncol (2010) 21 (suppl 5): v93-v97 Authors: E. Van Cutsem, B. Nordlinger, A.

Cervantes

10. Anal Cancer: ESMO Clinical Practice Guidelines; Published in 2010 – Ann Oncol 2010; 21 (Suppl 5): vi87-vi92. Authors: R. Glynne-Jones, J. M. A. Northover, A. Cervantes

Permission is granted for distribution of the above titles in the following publications:

- **Association of medicinal oncologists**
- **University Clinical Center Banja Luka**
- **University Clinical Center Istočno Sarajevo**

Association of medicinal oncologists also has the opportunity to translate additional ESMO Clinical Practice Guidelines titles during the term of this agreement on request subject to an agreed amendment to the permission agreement.

ESMO Clinical Practice Guidelines must be reproduced to the same high quality as the original publications. Translations must clearly state the publication date of the original document.

The **serbian language** translation of the above ESMO Clinical Practice Guidelines document is ESMO copyright owned. The translation must be carried out or reviewed by a nationally registered translator and validated by a medical oncologist representing the **Association of medicinal oncologists**. The translations must be exact translations of the parent document and shall consist of the whole of the textual, pictorial and diagrammatic material constituting the ESMO publication without alteration, abridgement or supplement and any comments/annotations etc. must be clearly indicated as not part of the original ESMO document, either in footnotes at the end of each page or at the end of the document.

Full credit will be given to ESMO and the authors of the ESMO Clinical Practice Guidelines and the translation will contain the names of all authors. It must be stated in the title or subtitle that it is a translation of the ESMO Clinical Practice Guidelines. An ESMO copyright statement must appear on the title page of the publication along with the full reference to the original publication in Annals of Oncology.

The names of translators, reviewers or others having worked on the translated version can be added at the beginning or end of the document and it must be clearly stated that they have worked on the translated version and not the parent document.

Association of medicinal oncologists must send ESMO an electronic version of the translated text and provide 4 examples of any printed material which is distributed for each title they translate for the ESMO archives. ESMO reserves the right to post the translation on the ESMO Web site or to create a link to the document on **Association of medicinal oncologists** Web site if it so desires. **Association of medicinal oncologists** will notify the ESMO Guidelines & Publishing Department of the date of publication and web-posting.

Association of medicinal oncologists has no right to sub-license this product or any part of it to any other parties or organizations. **Association of medicinal oncologists** may not give permission to any third party to post this translation on their website without prior approval from ESMO.



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

European Society for Medical Oncology

This agreement will terminate 29/11/2014. Renewal will be subject to approval by ESMO. In the event that any titles translated are updated by ESMO before the termination of this agreement, **Association of medicinal oncologists** must cease to distribute the relevant translation and seek permission from ESMO to translate the updated version.

This agreement in no way implies transfer of copyright to **Association of medicinal oncologists** and ESMO Clinical Practice Guidelines must not be distributed without agreement from ESMO.

ESMO Clinical Practice Guidelines must not be printed with commercial product advertising integrated into the document. If an unrestricted educational grant is obtained in order to cover the costs of translation and distribution, the sponsor may be acknowledged for this in the following way:

"Distributed through an educational grant from Company X. Company X was not involved in the development of this publication and in no way influenced its content"

Use of the ESMO logo must comply with ESMO rules for logo usage which can be consulted on the ESMO Web Site or supplied by ESMO.

No payment shall be made to ESMO by **Association of medicinal oncologists** in return for permission to translate the ESMO Clinical Practice Guidelines and ESMO will cover no costs in relation to this translation. **Association of medicinal oncologists** has no rights to sell ESMO Clinical Practice Guidelines in any format.

In witness whereof the ESMO and **Association of medicinal oncologists** have executed this agreement in duplicate by their duly authorized officers, an original being kept by each party.

For ESMO

Keith McGregor
Senior Director for Business Development
& Strategy, ESMO

Date: 29.11.2013.

Cc.

Claire Bramley, ESMO Guidelines & Publishing Manager
Saša Jungić, Editor in Chief

For Association of medicinal oncologists

Gordana Kecman Malčić
President of **Association of medicinal oncologists**

Date : 29.11.2013.